Latest News

New cotton mask kills 99.9% viruses, bacteria in an hour of sunlight, says study

November 12, 2020

A new cloth-based face mask has been developed by researchers that can kill up to 99.99 per cent of bacteria and viruses within 60 minutes of daylight exposure.

Reserachers have developed a reusable cotton face mask that can kill 99.9999 per cent of bacteria and viruses within an hour of exposure to sunlight, according to the study published in the journal ACS Applied Materials and Interfaces, news agency PTI reported. However, live bacteria and viruses on the surface of the mask could still be contagious.

Different types of COVID-19 tests explained

November 12, 2020

UC Davis Health is among the first in the nation to roll out a groundbreaking, highly accurate test that can check for both COVID-19 and flu viruses at the same time. It returns results in 20 minutes and the method of testing is considered the gold standard for coronavirus.

New Post-COVID-19 Clinic helps long-suffering long-haul patients

October 28, 2020
Rare combination of expert care and research

The region’s top experts in patient-focused pulmonary health will lead those multidisciplinary teams. A majority of long-haul COVID patients will experience a variety of respiratory symptoms but some may have more subtle symptoms that may require additional input from experts in cardiovascular, immunologic and neurologic medicine.

‘CRISPR and Coronavirus’: Hear From Nobel Winner Jennifer Doudna

October 20, 2020

The Office of Research and the School of Medicine had planned to introduce their Oct. 30 speaking guest as a professor and the founder and director of the Innovative Genomics Institute at UC Berkeley, and a CRISPR pioneer.

Since being booked for the Distinguished Speaker Series in Research and Innovation, however, Jennifer Doudna has added a new title: Nobel laureate.

What is an antibody cocktail and what trials are being done at UC Davis Health?

October 14, 2020
Q&A with Timothy Albertson on the antibodies President Trump received, clinical trials and the goals

Timothy Albertson, chair of internal medicine and specialist in pulmonary and critical care, is leading one of UC Davis Health’s two trials of Regeneron Pharmaceuticals’ antibody cocktail. He answers questions about the trials, the antibodies and how they might work.


Can an antibody ‘cocktail’ prevent COVID-19 infection?

October 12, 2020
In a new COVID-19 clinical trial, UC Davis Health tests the same REGN-COV2 antibody combination given to President Trump

In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients. The drug was recently administered to President Donald Trump as part of his treatment for SAR-CoV-2 infection.

Grants Available for Research Impacted by COVID-19

October 06, 2020

In mid-March, researchers at UC Davis were asked to adjust or reduce their work when possible in order to limit social contact and minimize the spread of the novel coronavirus. This “ramp down” meant that some campus research was postponed.


Campus Looks for Virus in Sewer System

October 06, 2020

Facilities Management and researchers are collecting and analyzing samples from the campus sewer system as one more tool to potentially identify and halt an outbreak of COVID-19.

Samples collected so far — all at the wastewater treatment plant — have returned mostly negative results. The team occasionally detected low levels of the coronavirus in samples collected in late August and September, consistent with cases of COVID-19 reported by the campus.


UC Davis to offer free COVID-19 testing for Central Valley farmworkers

October 02, 2020
A $3.7 million NIH grant will help reach underserved and vulnerable populations

Four UC Davis research centers will share a $3.7 million grant to offer free COVID-19 testing for agricultural workers in the Central Valley, where the coronavirus pandemic has reached alarming levels, the National Institutes of Health (NIH) announced Wednesday.


COVID-19 Science Six Months In: What Have We Learned?

September 25, 2020
Vaccines Will Help, but Masks and Social Distancing Will Be Crucial for Many Months

Although COVID-19 science has raced forward, the pandemic is likely to have an enormous impact on our lives deep into 2021, even with a vaccine on the horizon next year, two top UC Davis Health experts said this week on UC Davis LIVE: COVID-19.

Comparing Face Coverings in Controlling Expired Particles

September 24, 2020
Surgical, N95 Masks Block Most Particles

Laboratory tests of surgical and N95 masks by researchers at the University of California, Davis, show that they do cut down the amount of aerosolized particles emitted during breathing, talking and coughing. Tests of homemade cloth face coverings, however, show that the fabric itself releases a large amount of fibers into the air, underscoring the importance of washing them. The work is published Sept. 24 in Scientific Reports.

New OSCAR Clinical Trial for potential COVID-19 therapy at UC Davis Health

September 22, 2020
Trial will test otilimab as a treatment for severe lung disease

UC Davis Health has been selected as a site for a new clinical trial (OSCAR) to test otilimab as a potential treatment for severe pulmonary COVID-19-related disease.

Otilimab, a human monoclonal antibody, was under investigation as a treatment for rheumatoid arthritis. Now, the OSCAR clinical trial will evaluate the efficacy and safety of a single infusion of otilimab in treating severe lung inflammation in COVID-19 patients.


September 17, 2020
Clinicians, researchers, patients and the general public are invited to submit questions that could be answered by COVID-19 patient medical record data from 200+ hospitals

As the COVID-19 pandemic continues, there is an urgent need to determine who is at greatest risk for severe disease, better understand how the disease and treatments evolve, and predict the need for resources. But to get there, researchers and clinicians need more data about what patients have experienced so far, and what factors are associated with different patient outcomes.